The DOI matches its Crossref record.
Occult hepatitis B virus infection: a covert operation
Abstract
Detection of occult hepatitis B requires assays of the highest sensitivity and specificity with a lower limit of detection of less than 10 IU/mL for hepatitis B virus (HBV) DNA and <0.1 ng/mL for hepatitis B surface antigen (HBsAg). This covert condition is relatively common in patients with chronic hepatitis C virus (HCV) that seems to exert some influence on the replicative capacity and latency of HBV. Detection of virus-specific nucleic acid does not always translate into infectivity, and the occurrence of primer-generated HBV DNA that is of partial genomic length in immunocompetent individuals who have significant levels of hepatitis B surface antibody (anti-HBs) may not be biologically relevant. Acute flares of alanine aminotransferase (ALT) that occur during the early phase of therapy for HCV or ALT levels that remain elevated at the end of therapy in biochemical nonresponders should prompt an assessment for occult hepatitis B. Similarly, the plasma from patients with chronic hepatitis C that is hepatitis B core antibody (anti-HBc) positive (+/-anti-HBs at levels of <100 mIU/mL) should be examined for HBV DNA with the most sensitive assay available. If a liver biopsy is available, immunostaining for hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) should be contemplated and a portion of the sample tested for HBV DNA. This is another reason for optimal collection of a specimen (e.g. two passes with a 16-guage needle under ultrasound guidance). Transmission of HBV to immunosuppressed orthotopic liver transplant recipients by donors with occult hepatitis B (OHB) will continue to occupy the interests of the transplant hepatologist. As patients with OHB may have detectable HBV DNA in serum, peripheral blood mononuclear cells (PBMC) and/or liver that can be reactivated following immunosuppression or intensive cytotoxic chemotherapy, the patient needs to be either monitored or treated depending on the pretreatment serological results such as an isolated anti-HBc reaction or a detectable HBV DNA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Update of the statements on biology and clinical impact of occult hepatitis B virus infection
Raimondo, G., Locarnini, S., Pollicino, T., Levrero, M., Zoulim, F., Lok, A. S., Allain, J.-P., Berg, T., Bertoletti, A., Brunetto, M. R., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.034 · Cited by 572
Nucleic Acid Testing to Detect HBV Infection in Blood Donors
Stramer, S. L., Wend, U., Candotti, D., Foster, G. A., Hollinger, F. B., Dodd, R. Y., Allain, J.-P., & Gerlich, W. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007644 · Cited by 326
Self-citationHepatitis B virus PreS/S gene variants: Pathobiology and clinical implications
Pollicino, T., Cacciola, I., Saffioti, F., & Raimondo, G. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.04.041 · Cited by 277
Mak, L.-Y., Wong, D. K.-H., Pollicino, T., Raimondo, G., Hollinger, F. B., & Yuen, M.-F. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.05.042 · Cited by 223
Self-citation
Metadata
- Authors
- Hollinger, F. B., & Sood, G.
- Venue
- Journal of Viral Hepatitis
- Publisher
- Wiley
- Published
- 2010-01
- Volume
- 17
- Issue
- 1
- Pages
- 1-15
- ISSN
- 1352-0504 (ISSN-L)
- 1365-2893
- OpenAlex
- W1938307711
- Cited by
- 205
- References
- 0
- FWCI
- 9.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Occult hepatitis B virus infection: a covert operation. https://app.cochat.ai/papers/10.1111/j.1365-2893.2009.01245.x
- The paper
- Hollinger, F. B., & Sood, G. (2010). Occult hepatitis B virus infection: a covert operation. Journal of Viral Hepatitis. https://doi.org/10.1111/j.1365-2893.2009.01245.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.